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Abstract
Background: Diarrheal diseases are a major public health problem in developing countries, and are one of the
main causes of hospital admissions in Madagascar. The Pasteur Institute of Madagascar undertook a study to
determine the prevalence and the pathogenicity of bacterial, viral and protozoal enteropathogens in diarrheal and
non-diarrheal stools of children aged less than 5 years in Madagascar. We present here the results of the analysis of
antimicrobial susceptibility of the bacteria isolated during this study.
Methods: The study was conducted in the community setting in 14 districts of Madagascar from October 2008 to
May 2009. Conventional methods and PCR were used to identify the bacteria; antimicrobial susceptibility was
determined using an agar diffusion method for enterobacteriaceae and MICs were measured by an agar dilution
method for Campylobacter sp. In addition to the strains isolated during this study, Salmonella sp and Shigella sp
isolated at the Pasteur Institute of Madagascar from 2005 to 2009 were included in the analysis to increase the
power of the study.
Results: Twenty-nine strains of Salmonella sp, 35 strains of Shigella sp, 195 strains of diarrheagenic E. coli, 203 strains
of C. jejuni and 71 strains of C. coli isolated in the community setting were tested for antibiotic resistance. Fifty-five
strains of Salmonella sp and 129 strains of Shigella sp isolated from patients referred to the Pasteur Institute of
Madagascar were also included in the study. Many E. coli and Shigella isolates (around 80%) but fewer Salmonella
isolates were resistant to ampicillin and trimethoprim/sulfamethoxazole. A small proportion of strains of each
species were resistant to ciprofloxacin and only 3% of E. coli strains presented a resistance to third generation
cephalosporins due to the production of extended-spectrum beta-lactamases. The resistance of Campylobacter sp to
ampicillin was the most prevalent, whereas less than 5% of isolates were resistant to each of the other antibiotics.
Conclusion: The highest prevalence of antimicrobial resistance was to ampicillin and trimethoprim/
sulfamethoxazole. Antibiotic treatment is not recommended for children with diarrhea in Madagascar and the
emphasis should be placed on oral rehydration.
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Background
Diarrheal diseases are a major public health problem in
developing countries, especially in Africa [1,2]. More
than 1.8 million children under 5 years of age die of
diarrheal disease every year [2].
The agents capable of causing infectious diarrhea in-
clude a wide variety of bacteria, viruses, and parasites.
Treatment includes rehydration and in some cases anti-
microbial therapy. The acute diarrheal diseases for which
antimicrobial therapy is recommended include shigellosis,
campylobacteriosis and infection with Vibrio cholerae, V.
parahaemolyticus and V. vulnificus [3,4]. Improving our
knowledge of antimicrobial resistance among enteric path-
ogens is of particular importance in the developing world,
where the rate of diarrheal diseases is highest. The con-
tinuous increase in antimicrobial resistance among enteric
pathogens in developing countries is becoming a serious
concern. However, resistance patterns are often region-
specific, and are only very poorly documented in Africa.
The data available relating to antimicrobial resistance in
bacteria responsible for diarrheal disease in Madagascar is
limited. Few studies have described resistance patterns of
Shigella, and the most recent was more than 20 years ago
[5]; we found no reports concerning the antimicrobial
resistance Salmonella, Campylobacter or diarrheagenic
Escherichia coli in Madagascar.
The Pasteur Institute of Madagascar recently launched
a program to determine the prevalence and the patho-
genicity of bacterial, viral and protozoal enteropathogens
in diarrheal and non-diarrheal stools of children less than
5 years of age, in 14 different districts of Madagascar [6].
Here, we present an analysis of the antimicrobial resist-
ance of pathogens isolated in this study and of enteric
pathogens isolated from the stools of patients referred to
the Pasteur Institute of Madagascar for diarrheal disease.
Methods
Patients enrolled during the multicenter study
The study was conducted in 14 districts of Madagascar as
previously described (Figure 1) [6], from October 2008 to
May 2009 during the rainy season, for three consecutive
weeks at each site. The study was carried out in the com-
munity setting, not in hospitals or health centers. A mo-
bile laboratory well equipped (fridge, incubator, Bunsen,
microscope), installed in a four-wheel drive truck, was
used for the laboratory procedures in optimal field condi-
tions as soon as the stools were emitted. A generator was
used to maintain the electricity when the engine was
stopped. Temperatures of the fridge and the incubator
were controlled using an electronic thermometer. To
avoid contamination, stools were processed one by one
near the flame of the Bunsen.
Participants were randomly selected from children less
than 5 years of age in several villages in each district.
Participants provided clinical and epidemiological data
and a fecal sample for identification of bacterial, viral
and protozoal enteropathogens.
Diarrheic patients were children less than five years of
age with acute diarrhea (emission of three or more un-
formed stools within a 24 h period) without current
treatment. After emission of stools, all case patients re-
ceived treatment according to the World Health Organ-
isation guidelines for diarrheal disease [7].
Non diarrheic subjects were children under five years
of age with no history of diarrhea in the previous
3 months and were enrolled at the same time as case
subjects (one control for every three cases). Information
on demographic and historical clinical data were ob-
tained from parents of both cases and controls and re-
corded in questionnaires. There was no follow-up after
the initial recruitment of patients.
Patients referred to the Pasteur Institute
Retrospective data concerning the resistance to antibac-
terial drugs of strains of Salmonella and Shigella isolated
from patients referred to the Pasteur Institute from 2005
to 2009 were analysed in the study to increase the number
of strains and give a more complete view of the resistance
to antibacterial drugs in these species circulating in
Madagascar. For these patients fresh stools were brought
directly by the patients or their family to the Pasteur Insti-
tute and were processed within 2 hours after reception.
Laboratory procedures
Bacterial isolation and identification
Bacteria, including Salmonella spp., Shigella species, Cam-
pylobacter spp and Escherichia coli, were isolated using
standard microbiological procedures. Stool samples were
plated on Hektoen agar for the detection of Salmonella and
Shigella, Eosin Methylene Blue and Uriselect for the detec-
tion of E. coli and on Karmali agar for the detection of
Campylobacter. Plates were incubated at 37°C, under spe-
cific microaerophilic conditions for Campylobacter (campy-
gen, Oxoid, France). During the multicenter study, the
plates positive for colonies suspected to be pathogenic
Salmonella spp., Shigella species or E. coli and all Karmali
agar plates were sent at least every 2 days to the Pasteur
Institute for complete identification. Campylobacter spp. were
confirmed with the hemagglutination test-kit (Campy dry
spot, Oxoid, England), as recommended by the manufacturer.
Colonies typical of E. coli on EMB or Uriselect medium
were further tested by PCR for genes encoding virulence
factors associated with diarrheagenic E. coli [8].
Susceptibility testing
The antibiotic susceptibilities of all Salmonella, Shigella
and diarrheagenic E. coli isolates were determined by a
standard antibiotic disk diffusion technique according to
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the Antibiogram Committee of the French Microbiol-
ogy Society (CASFM) [9]. The antibiotics tested were
nalidixic acid, ciprofloxacin, amoxicillin, amoxicillin +
clavulanic acid, ticarcillin, ceftazidime, cefotaxime, cefoxi-
tin, gentamicin and trimethoprim-sulfamethoxazole.
Antimicrobial susceptibility was scored using the break-
point criteria, as defined by the CASFM [9]. Extended
Spectrum Betalactamase (ESBL) production was de-
duced from the resistance phenotype and results of the
double-disk synergy test using conventional combina-
tions (cefotaxime, ceftazidime, ceftriaxone vs. clavulanic
acid) [10].
Escherichia coli ATCC 25922, Staphylococcus aureus
ATCC 25923 and Pseudomonas aeruginosa ATCC 27853
were used as controls.
The minimum inhibitory concentrations (MICs) of five
antimicrobial agents were determined for Campylobacter
sp, using agar dilution methods. Two-fold serial dilutions
of antibiotics were added to molten Mueller–Hinton II
agar (Oxoid) supplemented with 5% sheep blood at a
temperature of 37°C. The plates were seeded with
104 cfu/spot of bacteria by means of a multipoint inocu-
lator and incubated at 35°C under CO2 for 48 h in a
microaerobic atmosphere (Campygen, Oxoid, France).
Figure 1 Map of Madagascar with the location of the sites where patients were enrolled during the multicenter study.
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The antimicrobials evaluated were ciprofloxacin, erythro-
mycin, ampicillin, tetracycline and gentamicin. Reference
strains Campylobacter coli ATCC 49941 and Campylobac-
ter jejuni subsp jejuni ATCC 49943 were used as controls
for both susceptibility testing and growth. The MIC break-
points used were those recommended by the CASFM [9].
Ethical issues
The national Ethics Committee of Madagascar approved
the research protocol. Informed consent was obtained
from all the participants either directly or through their
legal and competent guardians.
Statistical analysis
R software (R Foundation for Statistical Computing,
Vienna, Austria) was used for data analysis. In univariate
analysis, the two-tailed Fisher’s exact test was used to
compare categorical variables for antibiotic resistance
according to the study site (cross sectional community
study or diagnostic activities of the Pasteur Institute of
Madagascar). Factors identified by univariate analysis as
being associated with p-values <0.20 were retained for
multivariate analysis. Differences were considered sig-
nificant if the p-value was <0.05.
Results
Demographic characteristics of the patients included in the
multicenter study were already given in a previous article;
all patients were under 5 years old [6]. Concerning the pa-
tients presenting at the Pasteur Institute they were limited
to age; the median age was 6 (range: 4 months - 82 years),
and patients were divided in two groups (age < 5 years old,
n = 81) and patients > = 5 years old, n = 90) for the
analyses. Twenty-nine strains of Salmonella sp, 35 strains
of Shigella sp, 195 strains of diarrheagenic E. coli, 203
strains of C. jejuni and 71 strains of C. coli, isolated from
diarrheic and healthy children in the community [6], were
tested for antibiotic resistance. Fifty-five strains of Salmon-
ella sp and 129 strains of Shigella sp isolated from patients
referred to the Pasteur Institute of Madagascar were in-
cluded in the study. Among the Shigella isolates, 156
could be typed: there were 3 strains of S. boydii, 12
strains of S. dysenteriae, 99 strains of S. flexneri and 42
strains of S. sonnei.
Many of the Enterobacteriaceae were resistant to antibi-
otics widely used in Madagascar; in particular, resistance to
penicillin A and trimethoprim-sulfamethoxazole was highly
prevalent among Shigella and E. coli isolates (60% to 80% of
strains were resistant; Table 1), but less so among Salmon-
ella sp (35.7 of the strains were resistant to amoxicillin and
2.3% to trimethoprim-sulfamathoxazole) (Table 1). There
were no significant differences in rates of resistance be-
tween the different types of diarrheagenic E. coli.
Resistance to ampicillin and ticarcillin was significantly
more prevalent among Salmonella strains isolated from
patients referred to the Pasteur Institute of Madagascar
(29 of 55 strains, 52.7%) than among Salmonella strains iso-
lated in the community (one of 29 strains, 3.5%) (p < 0.01)
(Table 2). Resistance to third generation cephalosporin was
found only in one of 84 Salmonella strains (1.2%) and six of
195 of diarrheagenic E. coli (3.1%); all these resistant strains
presented a ESBL phenotype (synergy between third gene-
ration cephalosporins and clavulanic acid and susceptibility
to cefoxitin).
Significant differences in rates of resistance were also
found between S. flexneri isolated from patients referred
Table 1 Susceptibility of Salmonella, Shigella sp and diarrheagenic Escherichia coli isolated from stools of patients with
acute diarrhea, in Madagascar
Salmonella sp (n = 84) Shigella sp (n = 164) Diarrheagenic E. coli (n = 195)
Antimicrobial Resistant Intermediate Susceptible Resistant Intermediate Susceptible Resistant Intermediate Susceptible
N (%) (%) (%) (%) (%) (%) (%) (%) (%)
Amoxicillin 30 (35.7) 0 (0.0) 54 (64.3) 103 (62.8) 0 (0.0) 61 (37.2) 160 (82.1) 0 (0.0) 35 (17.9)
Amoxicillin/Clavulanic
acid
2 (2.3) 3 (3.6) 79 (94.1) 12 (7.3) 40 (24.4) 112 (68.3) 2 (1.0) 21 (10.8) 172 (88.2)
Ticarcillin 30 (35.7) 0 (0.0) 54 (64.3) 102 (62.2) 1 (0.6) 61 (37.2) 161 (82.6) 0 (0.0) 34 (17.4)
Cephalothin 2 (2.3) 3 (3.6) 79 (94.1) 14 (8.5) 37 (22.5) 113 (69) 6 (3.1) 11 (5.6) 178 (91.3)
Cefotaxime 1 (1.2) 0 (0.0) 83 (98.8) 0 (0.0) 0 (0.0) 164 (100) 6 (3.1) 0 (0.0) 189 (96.9)
Ceftazidime 1 (1.2) 0 (0.0) 83 (98.8) 0 (0.0) 0 (0.0) 164 (100) 3 (1.5) 3 (1.5) 189 (96.9)
Cefoxitin 0 (0.0) 0 (0.0) 84 (100) 0 (0.0) 0 (0.0) 164 (100) 0 (0.0) 1 (0.5) 194 (99.5)
Gentamicin 0 (0.0) 0 (0.0) 84 (100) 0 (0.0) 0 (0.0) 164 (100) 2 (1.0) 0 (0.0) 193 (99.0)
Nalidixic acid 1 (1.2) 2 (2.3) 81 (96.5) 1 (0.7) 0 (0.0) 163 (99.3) 21 (10.8) 0 (0.0) 174 (89.2)
Ciprofloxacin 0 (0.0) 0 (0.0) 84 (100) 0 (0.0) 0 (0.0) 164 (100) 6 (3.1) 0 (0.0) 189 (96.9)
Trimethoprim/
Sulfamethoxazole
2 (2.3) 0 (0.0) 82 (97.7) 131 (79.9) 5 (3.0) 28 (17.1) 165 (84.6) 2 (1.0) 28 (14.4)
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to the Pasteur Institute of Madagascar (n = 73) and S.
flexneri isolated in the community (n = 26) concerning
trimethoprime-sulfamathoxazole (74% vs. 100% of strains
being resistant, respectively, p < 0.01), nalidixic acid
(57.5% vs. 23%, respectively, p < 0.01) and amoxicillin/
clavulanic acid (58.9% vs. 23% respectively, p < 0.01)
(Table 2). There were differences in rates of resistance be-
tween S. flexneri and S. sonnei for amoxicillin and ticarcil-
lin (88.9% vs. 11.9% of strains were resistant, respectively,
p < 0.01), amoxicillin/clavulanic acid (49.5% vs. 0%, re-
spectively, p < 0.01) and cephalotin (48.5% vs. 0%, respect-
ively, p < 0.01). The only difference that persisted in
multivariate analysis was the type of patient included in
the study: at the Pasteur Institute of Madagascar or in the
community (Tables 2 and 3). Among the patients referred
to the Pasteur Institute of Madagascar, there was no differ-
ence between patients aged less than 5 years and those
aged more than 5 years, except for resistance to ampicillin
and ticarcillin in Salmonella; resistance to these drugs was
more prevalent among Salmonella isolates from patients
younger than 5 years old (P = 0.04) (Table 2).
There was a significant difference between the preva-
lence of resistance to ampicillin of C. jejuni and C. coli
(66.5% vs. 90.1%, respectively, p < 0.01, OR = 4.6, 95%CI
[1.9-12.5]) (Table 4). The rates of resistance to other
antibiotics, including tetracycline but excluding nalidixic
acid, were low (Table 4).
In the multicenter study in the community, there was
no significant difference in the rates of resistance to any
antibiotic between isolates from cases and those from
controls for any species, nor between isolates from dif-
ferent sites.
Discussion
Antibiotics are often used only as a supplemental tool to
treat diarrhea, with oral rehydration being the main
treatment. However, in developing countries where
many children are malnourished, it may be advisable to
use all tools to minimize the duration of the illness and
avoid severe dehydration. In most areas of developing
countries, bacterial identification is not feasible and
hence the antibiogram for each patient cannot be deter-
mined. Therefore, extensive knowledge of the prevalence
of antibiotic resistance among the various species in-
volved would be extremely valuable. Our study presents
the strength of having been conducted in 14 different
sites in Madagascar (Figure 1). It is therefore representa-
tive of the whole country, at least for diarrheagenic
E. coli and Campylobacter sp. We chose also to include
Salmonella and Shigella strains isolated at the Pasteur
Table 2 Percentage of isolates expressing resistance for Salmonella sp, Shigella flexneri and S. sonnei, according to the





Amx AMC CF TIC SXT
N % N % N % N % N %
S. flexneri PIM* (> = 5 years) 34 29 (85) 18 (53) 17 (50) 29 (85) 24 (71)
PIM (<5 years) 39 36 (92) 25 (69) 25 (69) 36 (92) 30 (77)
Transversal Study (<5 yrs) 26 23 (88) 6 (23) 6 (23) 23 (88) 26 (100)
p-value 0.63 0.04 0.05 0.63 <0.01
S. sonnei PIM (> = 5 years) 26 2 (8) 0 (0) 0 (0) 2 (8) 21 (81)
PIM (<5 years) 13 1 (8) 0 (0) 0 (0) 1 (8) 13 (100)
Transversal study (<5 yrs) 3 2 (67) 0 (0) 0 (0) 2 (67) 3 (100)
p-value 0.03 —— —— 0.03 0.17
Salmonella sp PIM (> = 5 years) 29 11 (38) 1 (3) 1 (3) 11 (38) 0 (0)
PIM (<5 years) 26 18 (69) 4 (15) 4 (15) 18 (69) 2 (8)
Transversal study (<5 yrs) 29 1 (3) 0 (0) 0 (0) 1 (3) 1 (3)
p-value <0.01 0.04 0.04 <0.01 0.30
*PIM: Pasteur Institute of Madagascar.
Table 3 Percentage of susceptible and intermediately susceptible (in brackets) isolates of the Shigella genera
Pathogens (No tested) AMX AMC TIC CF FOX CTX CAZ NA CIP GM SXT
Shigella species (8) 37.5 75 (25) 37.5 75 (25) 100 100 100 87.5 100 100 0 (12.5)
S. dysenteriae (12) 66.7 91.7 (8.3) 66.7 91.7 (8.3) 100 100 100 100 100 100 33.3
S. flexneri (99) 11.1 50.5 (37.4) 11.1 (1) 50.5 (37.4) 100 100 100 100 100 100 19.2 (4)
S. boydii (3) 66.7 100 66.7 100 100 100 100 100 100 100 0
S. sonnei (42) 88.1 100 88.1 100 100 100 100 100 100 100 11.9
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Institute of Madagascar to increase the scope of the
study. This may have introduced a bias, but any such
bias is probably minor because many of patients pre-
senting at the Pasteur Institute of Madagascar for diar-
rhea had traveled in the country immediately before the
onset of symptoms such that the strains isolated did not
all originate from Antananarivo. The age of patients is
also different but differences are mainly between pa-
tients presenting at the Pasteur Institute, whatever their
age, and those enrolled in the transversal study.
The prevalence of resistance of Shigella and E. coli to
ampicillin and cotrimoxazole were very high, and much
higher than those of Salmonella sp. They were similar to
the rates of resistance of E. coli isolated from urinary
tract infections in a previous study [11]. These rates of
resistance to ampicillin and cotrimoxazole are also simi-
lar to those observed in Botswana and Kenya, where the
differences in rates of resistance between Salmonella
and Shigella have also been reported [12,13]. During a
previous survey conducted in 1988–1989 in Madagascar,
rates of resistance of Shigella were different from those
we report here [5]. Resistance of S. dysenteriae to ampicil-
lin and cotrimoxazole were slightly more prevalent in the
previous study (69% vs. 63% and 38% vs. 0%, respectively)
whereas resistance of S. flexneri to penicillin A and cotri-
moxazole have become considerably more prevalent since
1989 (13% vs. 89% and 4.3% vs. 80%, respectively). In our
study, no resistance to ciprofloxacin was found in Salmon-
ella or Shigella isolates, in contrast to what has been de-
scribed elsewhere, for example on the Andaman Islands
[14]. However, according to the CASFM, strains of
Salmonella resistant or intermediately resistant to nali-
dixic acid should be categorized as resistant to fluoro-
quinolones [9]. Therefore three strains in our study should
be considered as resistant to ciprofloxacin.
Nevertheless, few of the diarrheagenic E. coli isolates
were resistant to ciprofloxacin (3.1%).
ESBL-producing E. coli were detected but the rates
were lower than those of rectal carriage of ESBL-
producing E. coli observed both in community settings
in Madagascar (6.4%) [15], and in children on admission
to a pediatric unit in Antananarivo (10%) [16]. This rate
was, however, similar to what was observed for E. coli
isolated from urinary tract infections in the community
[11]. The rates of ESBL-producing E. coli were also
lower than that observed in Cairo, Egypt (14.3%) [17],
but higher than in South America where rates of resist-
ance to ampicillin and cotrimoxazole are high whereas
no resistance to third generation cephalosporin has been
observed in Brazil or Peru [18,19].
Rates of resistance among Campylobacter sp were
similar to that found in 2005 for isolates from chickens
in Antananarivo [20]. The only major difference was that
resistance to erythromycin was less prevalent in our (5/
274, 2%) than the previous study (18.3% of resistant
strains).
The resistance of Campylobacter sp to antibiotics fre-
quently used for therapy in veterinary medicine in many
countries (tetracycline and ciprofloxacin) was much
lower in our study than reported in most other studies
[21-24]. It is likely that antibiotics are too expensive for
most farmers in Madagascar, and this would explain the
susceptibility of most strains in the country.
Rates of resistance were similar in diarrheic and
healthy children which is not surprising since strains
were probably clonally related in a village. This is also
compatible with the fact that the prevalence rates were
not different for all these strains between diarrheic and
healthy children [6].
In a previous article, we described the types of patho-
gens detected in this study, and reported that intestinal
pathogens were the most frequently encountered. Giar-
dia lamblia, Trichomonas intestinalis and Entamoeba
histolytica were the only pathogens that were detected at
a higher frequency in patients with diarrhea than in pa-
tients without diarrhea [6]. These results and those of
our antimicrobial susceptibility study argue strongly for
a reasoned use of antibiotics to treat diarrhea in children
in Madagascar. Indeed, other than Salmonella, which
are rarely isolated and for which antibiotics are not rec-
ommended, the most common enterobacteria (Shigella
and E. coli) isolated from such patients are resistant to
penicillin A and cotrimoxazole in nearly four of every
five cases. The only available antibiotic that can be
Table 4 Susceptibility of Campylobacter sp isolated from stools of patients with acute diarrhea, in Madagascar
C. jejuni C. coli
Susceptible Intermediate Resistant Susceptible Intermediate Resistant
n % n % n % n % n % n %
Erythromycin 160 (78.8) 41 (20.2) 2 (1.0) 50 (70.4) 18 (25.4) 3 (4.2)
Ampicillin 68 (33.5) 95 (46.8) 40 (19.7) 7 (9.9) 36 (50.7) 28 (39.4)
Gentamycin 202 (99.5) 1 (0.5) 0 (0.0) 71 (100.0) 0 (0.0) 0 (0.0)
Tetracycline 201 (99.0) 0 (0.0) 2 (1.0) 70 (98.6) 0 (0.0) 1 (1.4)
Ciprofloxacin 199 (98.0) 2 (1.0) 2 (1.0) 67 (94.4) 0 (0.0) 4 (5.6)
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administered orally and likely to be effective is ciproflo-
xacin which is not recommended in children.
Conclusions
Our study shows a high prevalence of antimicrobial resis-
tance to ampicillin and trimethoprim/sulfamethoxazole.
These results and the fact that parasites are frequently re-
sponsible for diarrhea in Malagasy children imply that anti-
biotic treatment is not recommended for children with
diarrhea in Madagascar. Therefore, we believe that emphasis
should be placed on the importance of oral rehydration in
the management of diarrhea in children in Madagascar.
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